Regeneron Pharmaceuticals Inc
$ 764.93
-2.87%
05 Mar - close price
- Market Cap 83,254,346,000 USD
- Current Price $ 764.93
- High / Low $ 781.99 / 760.01
- Stock P/E 18.98
- Book Value 304.65
- EPS 41.50
- Next Earning Report 2026-04-30
- Dividend Per Share $3.52
- Dividend Yield 0.46 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 820.12
- 52 Week Low 474.60
About
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Analyst Target Price
$870.73
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-30 | 2025-10-30 | 2025-08-01 | 2025-04-29 | 2025-02-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-02 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 11.44 | 11.83 | 12.89 | 8.22 | 12.07 | 12.46 | 11.56 | 9.55 | 11.86 | 11.59 | 10.24 | 10.09 |
| Estimated EPS | 10.52 | 9.67 | 8.44 | 8.48 | 11.19 | 11.7 | 10.61 | 10.09 | 10.73 | 10.72 | 9.84 | 9.56 |
| Surprise | 0.92 | 2.16 | 4.45 | -0.26 | 0.88 | 0.76 | 0.95 | -0.54 | 1.13 | 0.87 | 0.4 | 0.53 |
| Surprise Percentage | 8.7452% | 22.3371% | 52.7251% | -3.066% | 7.8642% | 6.4957% | 8.9538% | -5.3518% | 10.5312% | 8.1157% | 4.065% | 5.5439% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 9.16 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|---|
| Payment Date | 2026-03-05 | 2025-12-05 | 2025-09-03 | 2025-06-06 | 2025-03-20 |
| Amount | $0.94 | $0.88 | $0.88 | $0.88 | $0.88 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: REGN
2026-03-05 21:12:53
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that its management will participate in the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, at 9:00 a.m. ET. A webcast of the session will be available on the "Investors & Media" page of Regeneron's website, with a replay and transcript archived for at least 30 days. Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases.
2026-03-05 20:50:51
This article analyzes Regeneron Pharmaceuticals (REGN) to determine if its current share price offers good value. Using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio analyses, the stock appears undervalued, with the DCF model suggesting a 55.5% discount and the P/E ratio being below industry and peer averages. The article also presents bull and bear case narratives, highlighting the range of potential fair values based on different assumptions about growth, competition, and pipeline success.
2026-03-05 14:14:55
The Alliance for Genomic Discovery (AGD) has expanded its membership with Regeneron Genetics Center (RGC), increasing its core dataset to 312,000 whole genomes. Additionally, the AGD announced a new initiative to create a dataset of 50,000 whole genomes paired with proteomic data, with GSK as one of the first participants. These advancements aim to accelerate drug discovery and develop new treatments by integrating extensive genomic and clinical data with advanced AI and multiomic insights.
2026-03-05 08:50:51
Regeneron Pharmaceuticals Inc. experienced a 3.05% drop in its stock, reaching an intraday low of $764.49, contrasting with a smaller decline in the S&P 500. Despite this short-term pressure, the company maintains a strong market position with a large market capitalization, high return on equity, low debt-to-equity ratio, and significant institutional support. Year-to-date, Regeneron has seen a slight decline, but its annual return remains positive.
2026-03-05 02:33:03
Facing impending patent losses on key products like Otezla and Enbrel, Amgen is strategically repositioning its business for long-term growth. The company plans to achieve its "ambitious growth aspirations" by expanding its biosimilar portfolio, focusing R&D on four therapeutic areas (oncology, general medicine, inflammation, rare disease), and maximizing its existing product impact, including the obesity drug candidate MariTide. Amgen expects biosimilar sales to reach $4 billion by 2030 and continues to pursue acquisitions like Horizon Therapeutics to boost its market presence.
2026-03-04 21:50:56
Jim Cramer expressed regret for not investing in Regeneron Pharmaceuticals (NASDAQ:REGN) earlier, noting its strong performance and his missed opportunity. He acknowledged that the company, which develops medicines for various conditions, would have been a better drug stock for his Charitable Trust than some of their current holdings, with the exception of Eli Lilly. Cramer mentioned his admiration for Regeneron’s quiet but significant progress, despite overlooking it himself.
